Literature DB >> 2336086

Platelet hyperreactivity and prognosis in survivors of myocardial infarction.

M D Trip1, V M Cats, F J van Capelle, J Vreeken.   

Abstract

We tested the hypothesis that an increase in spontaneous aggregability of platelets in vitro predicts mortality and coronary events in patients who have survived a recent myocardial infarction. A cohort of 149 survivors of infarction entered our study three months after the index infarction and was followed for five years. At entry and at intervals of six months, spontaneous platelet aggregation (SPA) was tested and graded as positive (aggregation within 10 minutes), intermediate (aggregation after 10 to 20 minutes), or negative (no aggregation within 20 minutes). During follow-up, 6.4 percent (6 of 94) of the patients in the SPA-negative group died, as compared with 10.3 percent (3 of 29) in the SPA-intermediate group and 34.6 percent (9 of 26) in the SPA-positive group. As compared with the SPA-negative group, the SPA-intermediate group had a relative risk of death of 1.6 (95 percent confidence interval, 0.5 to 5.5) and the SPA-positive group had a risk of 5.4 (95 percent confidence interval, 2.2 to 13.4). At least one cardiac event (cardiac death or recurrent nonfatal myocardial infarction) occurred in 14.9 percent (14 of 94 patients) of the SPA-negative group, 24.1 percent (7 of 29) of the SPA-intermediate group, and 46.2 percent (12 of 26) of the SPA-positive group. A positive test result continued to have prognostic value throughout the five-year study. We conclude that spontaneous platelet aggregation in vitro is a useful biologic marker for the prediction of coronary events and mortality in this low-risk group of survivors of a myocardial infarction. A causal relation is suggested but not proved by our study.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2336086     DOI: 10.1056/NEJM199005313222201

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  104 in total

Review 1.  Oral glycoprotein IIb/IIIa antagonists in coronary artery disease.

Authors:  D P Chew; D L Bhatt
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

Review 2.  Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics.

Authors:  P J Goldschmidt-Clermont; C M Roos; G E Cooke
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

Review 3.  Pathogenesis and pathology of coronary heart disease syndromes.

Authors:  P M Ridker; E M Antman
Journal:  J Thromb Thrombolysis       Date:  1999-10       Impact factor: 2.300

4.  High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists.

Authors:  D J Kereiakes; T M Broderick; E M Roth; D Whang; M Mueller; P Lacock; L C Anderson; W Howard; C Blanck; J Schneider; C A Abbottsmith
Journal:  J Thromb Thrombolysis       Date:  2000-02       Impact factor: 2.300

5.  Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort.

Authors:  P C Elwood; S Renaud; A D Beswick; J R O'Brien; P M Sweetnam
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

6.  Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.

Authors:  D J Kereiakes; T Lorenz; J J Young; G Kukielka; M N Mueller; L Nanniazzi-Alaimo; D R Phillips
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

Review 7.  Function and clinical significance of platelet-derived microparticles.

Authors:  S Nomura
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

8.  PGE2 decreases reactivity of human platelets by activating EP2 and EP4.

Authors:  James P Smith; Elias V Haddad; Jason D Downey; Richard M Breyer; Olivier Boutaud
Journal:  Thromb Res       Date:  2010-05-08       Impact factor: 3.944

Review 9.  Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease?

Authors:  Wei Jiang; Ranga R Krishnan
Journal:  Curr Psychiatry Rep       Date:  2004-06       Impact factor: 5.285

10.  Activation of platelets upon contact with a vitamin E-coated/non-coated surface.

Authors:  Hiroshi Tsukao; Kenichi Kokubo; Haruko Takahashi; Mina Nagasato; Takanori Endo; Naoto Iizuka; Toshihiro Shinbo; Minoru Hirose; Hirosuke Kobayashi
Journal:  J Artif Organs       Date:  2013-02-05       Impact factor: 1.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.